Ashwin Sriram
Overview
Explore the profile of Ashwin Sriram including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Srinivas N, Song L, Lei K, Gravemeyer J, Furtmann F, Gambichler T, et al.
J Cancer Res Clin Oncol
. 2023 Apr;
149(11):8267-8277.
PMID: 37071208
Background: Class I selective histone deacetylase inhibitors (HDACi) have been previously demonstrated to not only increase major histocompatibility complex class I surface expression in Merkel cell carcinoma (MCC) cells by...
2.
Stiefel J, Freese C, Sriram A, Alebrand S, Srinivas N, Sproll C, et al.
Eng Life Sci
. 2022 May;
22(5):391-406.
PMID: 35573135
Detailed examination of tumor components is leading-edge to establish personalized cancer therapy. Accompanying research on cell-free DNA, the cell count of circulating tumor cells (CTCs) in patient blood is seen...
3.
Gravemeyer J, Lange A, Ritter C, Spassova I, Song L, Picard D, et al.
J Invest Dermatol
. 2021 Feb;
141(7):1675-1686.e4.
PMID: 33600825
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer characterized by high invasiveness, early metastases, and high mortality. Because of the lack of suitable animal models, most functional studies...
4.
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
Peiffer L, Farahpour F, Sriram A, Spassova I, Hoffmann D, Kubat L, et al.
Cancer Immunol Immunother
. 2020 Dec;
70(6):1635-1647.
PMID: 33275172
Background: Combined inhibition of BRAF/MEK is an established therapy for melanoma. In addition to its canonical mode of action, effects of BRAF/MEK inhibitors on antitumor immune responses are emerging. Thus,...
5.
Song L, Bretz A, Gravemeyer J, Spassova I, Muminova S, Gambichler T, et al.
J Invest Dermatol
. 2020 Oct;
141(4):903-912.e4.
PMID: 33002502
Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer for which immune modulation by immune checkpoint inhibitors shows remarkable response rates. However, primary or secondary resistance to immunotherapy...
6.
Chen I, Bender M, Spassova I, Henning S, Kubat L, Fan K, et al.
J Cancer Res Clin Oncol
. 2020 Sep;
146(12):3215-3231.
PMID: 32865618
Purpose: UV exposure is the main risk factor for development of cutaneous squamous cell carcinoma (cSCC). While early detection greatly improves cSCC prognosis, locally advanced or metastatic cSCC has a...
7.
Scialo F, Sriram A, Stefanatos R, Spriggs R, Loh S, Martins L, et al.
Redox Biol
. 2020 Mar;
32:101450.
PMID: 32146156
Reactive Oxygen Species (ROS) are essential cellular messengers required for cellular homeostasis and regulate the lifespan of several animal species. The main site of ROS production is the mitochondrion, and...
8.
Sriram A, Bohlen J, Teleman A
EMBO Rep
. 2018 Sep;
19(10).
PMID: 30224410
Recent work has brought to light many different mechanisms of translation initiation that function in cells in parallel to canonical cap-dependent initiation. This has important implications for cancer. Canonical cap-dependent...
9.
Scialo F, Sriram A, Stefanatos R, Sanz A
PLoS One
. 2016 Aug;
11(8):e0161817.
PMID: 27570965
Drosophila melanogaster is a popular research model organism thanks to its' powerful genetic tools that allow spatial and temporal control of gene expression. The inducible GeneSwitch Gal4 system (GS) system...
10.
Scialo F, Sriram A, Fernandez-Ayala D, Gubina N, Lohmus M, Nelson G, et al.
Cell Metab
. 2016 Apr;
23(4):725-34.
PMID: 27076081
Increased production of reactive oxygen species (ROS) has long been considered a cause of aging. However, recent studies have implicated ROS as essential secondary messengers. Here we show that the...